August 28, 2015
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

# Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS

TOKYO, Japan, August 27, 2015 --- SymBio Pharmaceuticals limited (Headquarters: Tokyo, "SymBio") announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") has submitted a Clinical Trial Applications (CTAs) with the United Kingdom, German and Austrian regulatory agencies for IV rigosertib in the treatment of higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agent (HMA) therapy. Upon CTA clearance, Onconova plans to initiate a single, randomized controlled global Phase 3 pivotal trial (04-30 trial) in patients with this HR-MDS indication.

SymBio expects to complete the ongoing Phase 1 trial for IV rigosertib (SyB L-1101) in the treatment of relapsed or refractory HR-MDS patients this October 2015. After consulting with the PMDA (Japanese Pharmaceuticals and Medical Devices Agency), SymBio plans to participate in the global 04-30 trial and to begin enrolling patients in Japan.

For more details in this press release, please visit Onconova's homepage at
http://investor.onconova.com/releases.cfm

**[Contact]**
Investor Relations
Tel: +81 (0)3 5472 1125